Pressure BioSciences, Inc. (PBIO)
OTCMKTS: PBIO · Delayed Price · USD
0.0007
-0.2192 (-99.68%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Pressure BioSciences Revenue
In the year 2023, Pressure BioSciences had annual revenue of $1.98M with 14.36% growth. Revenue in the quarter ending December 31, 2023 was $312.35K.
Revenue (ttm)
$1.98M
Revenue Growth
+14.36%
P/S Ratio
0.01
Revenue / Employee
$123,610
Employees
16
Market Cap
24.30K USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.98M | 248.42K | 14.36% |
Dec 31, 2022 | 1.73M | -273.02K | -13.63% |
Dec 31, 2021 | 2.00M | 781.77K | 64.05% |
Dec 31, 2020 | 1.22M | -589.40K | -32.56% |
Dec 31, 2019 | 1.81M | -647.88K | -26.36% |
Dec 31, 2018 | 2.46M | 217.37K | 9.70% |
Dec 31, 2017 | 2.24M | 264.01K | 13.36% |
Dec 31, 2016 | 1.98M | 178.80K | 9.95% |
Dec 31, 2015 | 1.80M | 422.95K | 30.77% |
Dec 31, 2014 | 1.37M | -128.54K | -8.55% |
Dec 31, 2013 | 1.50M | 265.07K | 21.41% |
Dec 31, 2012 | 1.24M | 250.49K | 25.36% |
Dec 31, 2011 | 987.73K | -352.30K | -26.29% |
Dec 31, 2010 | 1.34M | 95.12K | 7.64% |
Dec 31, 2009 | 1.24M | 392.65K | 46.07% |
Dec 31, 2008 | 852.26K | 206.39K | 31.96% |
Dec 31, 2007 | 645.87K | 435.58K | 207.13% |
Dec 31, 2006 | 210.29K | 104.76K | 99.28% |
Dec 31, 2005 | 105.53K | -307.09K | -74.43% |
Dec 31, 2004 | 412.62K | -22.88M | -98.23% |
Dec 31, 2003 | 23.30M | 531.05K | 2.33% |
Dec 31, 2002 | 22.76M | 938.53K | 4.30% |
Dec 31, 2001 | 21.83M | 2.36M | 12.10% |
Dec 31, 2000 | 19.47M | -9.83M | -33.55% |
Dec 31, 1999 | 29.30M | 3.20M | 12.26% |
Dec 31, 1998 | 26.10M | 3.80M | 17.04% |
Dec 31, 1997 | 22.30M | 6.80M | 43.87% |
Dec 31, 1996 | 15.50M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 379.49B |
Johnson & Johnson | 81.80B |
Merck & Co. | 61.40B |
AbbVie | 54.40B |
Novartis AG | 48.86B |
AstraZeneca | 47.61B |
Thermo Fisher | 42.49B |
Eli Lilly | 35.93B |
PBIO News
- 26 days ago - Pressure BioSciences Partners with Vita-Forte, Largest Global Supplier of Freeze-Dried Acai, to Commercialize Highly Potent, Multi-Antioxidant, UST Nanoemulsion Oral Spray - GlobeNewsWire
- 4 weeks ago - Pressure BioSciences, Inc. to Host Business and Financial Update on Thursday, June 20th at 4:30pm ET - GlobeNewsWire
- 5 weeks ago - Pressure BioSciences, Inc. to Host Business and Financial Update on Wednesday, June 19th at 4:30pm ET - GlobeNewsWire
- 3 months ago - Pressure BioSciences' Uncle Bud's Subsidiary Reports Significant Demand for New UltraShear CBD Body Revive Spray – First Product in New “Premium Collection” - GlobeNewsWire
- 5 months ago - Uncle Bud's Health & Wellness Experiencing Powerful Growth One Month Following Acquisition by Pressure BioSciences, Inc. - GlobeNewsWire
- 5 months ago - Pressure BioSciences Completes Relocation into New Manufacturing Facility, Consolidating R&D with Expanded UltraShear Equipment Development and Contract Manufacturing - GlobeNewsWire
- 6 months ago - Uncle Bud's to Launch New Premium Health and Wellness Products Leveraging Pressure BioSciences UltraShear Processing for Revolutionary Product Effectiveness - GlobeNewsWire
- 6 months ago - Pressure BioSciences Upcoming Investor Call to Discuss Recent Acquisition of Uncle Buds - GlobeNewsWire